AR051758A1 - Composicion de dispersion solida de pranlukast con biodisponibilidad mejorada y metodo para preparar la dispersion solida - Google Patents
Composicion de dispersion solida de pranlukast con biodisponibilidad mejorada y metodo para preparar la dispersion solidaInfo
- Publication number
- AR051758A1 AR051758A1 ARP050104618A ARP050104618A AR051758A1 AR 051758 A1 AR051758 A1 AR 051758A1 AR P050104618 A ARP050104618 A AR P050104618A AR P050104618 A ARP050104618 A AR P050104618A AR 051758 A1 AR051758 A1 AR 051758A1
- Authority
- AR
- Argentina
- Prior art keywords
- solid dispersion
- pranlukast
- composition
- improved
- prepare
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020040089455A KR101086254B1 (ko) | 2004-11-04 | 2004-11-04 | 생체이용률이 개선된 프란루카스트 고체분산체 조성물 및그 고체분산체의 제조방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR051758A1 true AR051758A1 (es) | 2007-02-07 |
Family
ID=36319405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050104618A AR051758A1 (es) | 2004-11-04 | 2005-11-03 | Composicion de dispersion solida de pranlukast con biodisponibilidad mejorada y metodo para preparar la dispersion solida |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP5232472B2 (enExample) |
| KR (1) | KR101086254B1 (enExample) |
| AR (1) | AR051758A1 (enExample) |
| MX (1) | MX2007005427A (enExample) |
| TW (1) | TWI380829B (enExample) |
| WO (1) | WO2006049433A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101233235B1 (ko) * | 2005-08-26 | 2013-02-15 | 에스케이케미칼주식회사 | 초기 용출율이 개선된 프란루카스트 고체분산체의 약제학적조성물 및 그의 제조방법 |
| CA2697099C (en) | 2007-08-21 | 2018-02-20 | Board Of Regents, The University Of Texas System | Thermo-kinetic mixing for pharmaceutical applications |
| EP4008314A3 (en) * | 2007-08-21 | 2022-11-09 | Board of Regents, The University of Texas System | Thermo-kinetic mixing for pharmaceutical applications |
| EP2140861A1 (en) | 2008-06-30 | 2010-01-06 | Abbott GmbH & Co. KG | Pharmaceutical dosage form comprising polymeric carrier composition |
| GB201103837D0 (en) * | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| KR101381881B1 (ko) * | 2012-03-12 | 2014-04-04 | 충남대학교산학협력단 | 용해도 및 용출율이 개선된 프란루카스트 나노 고체 분산체의 제조방법 |
| KR101446129B1 (ko) * | 2012-10-10 | 2014-10-06 | 조선대학교산학협력단 | 프란루카스트-함유 고형 제제의 제조방법 |
| KR102191562B1 (ko) * | 2012-11-07 | 2020-12-15 | 에스케이바이오팜 주식회사 | 난용성 약물의 고체분산체 및 이의 제조방법 |
| KR102363727B1 (ko) | 2015-06-01 | 2022-02-16 | 삼아제약 주식회사 | 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법 |
| WO2020012498A1 (en) | 2018-07-13 | 2020-01-16 | Council Of Scientific & Industrial Research | Solid dispersion comprising an anticancer compound with improved solubility and efficacy |
| KR20240164596A (ko) | 2023-05-09 | 2024-11-20 | 삼아제약 주식회사 | 복약편의성이 증진된 프란루카스트 함유 약제학적 조성물 |
| KR102840220B1 (ko) * | 2023-07-18 | 2025-07-31 | 삼아제약 주식회사 | 프란루카스트 함유 약제학적 조성물의 제조방법 및 상기 제조방법에 의해 제조된 약제학적 조성물 |
| KR20250052834A (ko) | 2023-10-12 | 2025-04-21 | 주식회사 다산제약 | 프란루카스트의 생체이용률이 개선된 약제학적 조성물 및 그 제조방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19509807A1 (de) * | 1995-03-21 | 1996-09-26 | Basf Ag | Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen |
| WO1996041628A1 (en) * | 1995-06-12 | 1996-12-27 | Ono Pharmaceutical Co., Ltd. | Granules containing pranlukast, process for producing the granules, and method of lowering cohesiveness of pranlukast |
| US5858509A (en) * | 1996-11-15 | 1999-01-12 | Digital Equipment Corporation | Attenuating vibrations in a mounting shelf for multiple disk drives |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| KR100381834B1 (ko) * | 2000-05-20 | 2003-04-26 | 이상득 | 용출성이 개선된 프란루카스트 고체분산체 조성물 및 그제조 방법 |
| UA80393C2 (uk) | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці |
-
2004
- 2004-11-04 KR KR1020040089455A patent/KR101086254B1/ko not_active Expired - Lifetime
-
2005
- 2005-11-03 AR ARP050104618A patent/AR051758A1/es unknown
- 2005-11-03 WO PCT/KR2005/003686 patent/WO2006049433A1/en not_active Ceased
- 2005-11-03 MX MX2007005427A patent/MX2007005427A/es not_active Application Discontinuation
- 2005-11-03 JP JP2007540251A patent/JP5232472B2/ja not_active Expired - Fee Related
- 2005-11-04 TW TW094138786A patent/TWI380829B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR101086254B1 (ko) | 2011-11-24 |
| TWI380829B (zh) | 2013-01-01 |
| MX2007005427A (es) | 2012-10-02 |
| JP5232472B2 (ja) | 2013-07-10 |
| JP2008519067A (ja) | 2008-06-05 |
| TW200621307A (en) | 2006-07-01 |
| KR20060040211A (ko) | 2006-05-10 |
| WO2006049433A1 (en) | 2006-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR051758A1 (es) | Composicion de dispersion solida de pranlukast con biodisponibilidad mejorada y metodo para preparar la dispersion solida | |
| AR029278A1 (es) | Metodo para preparar una composicion | |
| PE20060003A1 (es) | Formulacion farmaceutica polimerica para moldear por inyeccion | |
| CR9292A (es) | Comprimidos con dispersion mejorada de la sustancia farmacologica | |
| PE20061449A1 (es) | Composiciones farmaceuticas comprendiendo imatinib y un retardador de liberacion | |
| BRPI0707044B8 (pt) | comprimido matricial insolúvel em água e processo de fabricação de comprimidos matriciais | |
| AR045352A1 (es) | Forma de dosificacion a prueba de abuso | |
| EA200870559A1 (ru) | Стабильная фармацевтическая композиция, содержащая доцетаксел, и способ изготовления таковой | |
| CO6150131A2 (es) | Sistema de liberacion controlada y metodo para fabricarlo | |
| RU2005111222A (ru) | Пероральные композиции | |
| EA200600566A1 (ru) | Быстрорастворимая лекарственная форма соединения, действующего на кальциевый рецептор | |
| WO2004062577A3 (en) | Two or more enteric materials to regulate drug release | |
| AR072245A1 (es) | Proceso para minimizar el polimorfismo, forma de dosaje de dispersion rapida solida oral | |
| RU2016136636A (ru) | Аморфная твердая дисперсия, содержащая таксан, таблетка, содержащая такую дисперсию, и способ их получения | |
| EA200401583A1 (ru) | Таблетка лазофоксифена и ее покрытие | |
| ATE235240T1 (de) | Wässriges verfahren zur herstellung fester paroxetin-dispersionen | |
| RU2017101833A (ru) | Орально распадающийся пленочный препарат, содержащий тадалафил, и способ его приготовления | |
| RU2011112362A (ru) | Твердые препаративные формы оспемифена | |
| MX351059B (es) | Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion. | |
| BRPI0614545B8 (pt) | composição farmacêutica de liberação controlada, seu processo de produção, forma de dosagem oral com revestimento entérico de pacreatina e uso da mesma | |
| MA28342A1 (fr) | Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. | |
| ES2531241T3 (es) | Composición farmacéutica líquida estable a base de trazodona | |
| PT1263413E (pt) | Metodo de preparacao de dispersoes solidas | |
| AR062204A1 (es) | Formas solidas de (3'-clorobifeni-4-il)(1-pirimidin-2-il)piperidin-4-il)metanona, un metodo de preparacion, una dosificacion farmaceutica que la comprende y su uso en eltratamiento de trastornos cognitivos y de la enfermedad de alzheimer. | |
| AR050637A1 (es) | Implantes y microesferas de liberacion prolongada de farmacos de uso oftalmico y metodos para prepararlos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |